These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31943020)

  • 1. Enzyme replacement therapy in mice lacking arylsulfatase B targets bone-remodeling cells, but not chondrocytes.
    Hendrickx G; Danyukova T; Baranowsky A; Rolvien T; Angermann A; Schweizer M; Keller J; Schröder J; Meyer-Schwesinger C; Muschol N; Paganini C; Rossi A; Amling M; Pohl S; Schinke T
    Hum Mol Genet; 2020 Mar; 29(5):803-816. PubMed ID: 31943020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lysosomal Protein Arylsulfatase B Is a Key Enzyme Involved in Skeletal Turnover.
    Pohl S; Angermann A; Jeschke A; Hendrickx G; Yorgan TA; Makrypidi-Fraune G; Steigert A; Kuehn SC; Rolvien T; Schweizer M; Koehne T; Neven M; Winter O; Velho RV; Albers J; Streichert T; Pestka JM; Baldauf C; Breyer S; Stuecker R; Muschol N; Cox TM; Saftig P; Paganini C; Rossi A; Amling M; Braulke T; Schinke T
    J Bone Miner Res; 2018 Dec; 33(12):2186-2201. PubMed ID: 30075049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI.
    Nagpal R; Georgi G; Knauth S; Schmid-Herrmann C; Muschol N; Braulke T; Kahl-Nieke B; Amling M; Schinke T; Koehne T; Petersen J
    Front Physiol; 2022; 13():998039. PubMed ID: 36213247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver-Directed Adeno-Associated Virus-Mediated Gene Therapy for Mucopolysaccharidosis Type VI.
    Brunetti-Pierri N; Ferla R; Ginocchio VM; Rossi A; Fecarotta S; Romano R; Parenti G; Yildiz Y; Zancan S; Pecorella V; Dell'Anno M; Graziano M; Alliegro M; Andria G; Santamaria F; Brunetti-Pierri R; Simonelli F; Nigro V; Vargas M; Servillo G; Borgia F; Soscia E; Gargaro M; Funghini S; Tedesco N; Le Brun PR; Rupar CA; Prasad C; O'Callaghan M; Mitchell JJ; Danos O; Marteau JB; Galimberti S; Valsecchi MG; Veron P; Mingozzi F; Fallarino F; la Marca G; Sivri HS; Auricchio A
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2200052. PubMed ID: 38319253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle.
    Tessitore A; Faella A; O'Malley T; Cotugno G; Doria M; Kunieda T; Matarese G; Haskins M; Auricchio A
    Mol Ther; 2008 Jan; 16(1):30-7. PubMed ID: 17955027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.
    Fillat C; Simonaro CM; Yeyati PL; Abkowitz JL; Haskins ME; Schuchman EH
    J Clin Invest; 1996 Jul; 98(2):497-502. PubMed ID: 8755662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy.
    Karageorgos L; Harmatz P; Simon J; Pollard A; Clements PR; Brooks DA; Hopwood JJ
    Hum Mutat; 2004 Mar; 23(3):229-33. PubMed ID: 14974081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].
    Zheng J; Huang Y; Zhao X; Sheng H; Cheng J; Zhou Z; Li X; Mao X; Liu L
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):403-8. PubMed ID: 25190157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal development.
    Hwang-Wong E; Amar G; Das N; Zhang X; Aaron N; Gale K; Rothman N; Fante M; Baik A; Bhargava A; Fricker A; McAlister M; Rabinowitz J; Lees-Shepard J; Nannuru K; Economides AN; Cygnar KD
    JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37751300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
    Furujo M; Kubo T; Kosuga M; Okuyama T
    Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I.
    Kuehn SC; Koehne T; Cornils K; Markmann S; Riedel C; Pestka JM; Schweizer M; Baldauf C; Yorgan TA; Krause M; Keller J; Neven M; Breyer S; Stuecker R; Muschol N; Busse B; Braulke T; Fehse B; Amling M; Schinke T
    Hum Mol Genet; 2015 Dec; 24(24):7075-86. PubMed ID: 26427607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in ARSB in MPS VI patients in India.
    Mathew J; Jagadeesh SM; Bhat M; Udhaya Kumar S; Thiyagarajan S; Srinivasan S
    Mol Genet Metab Rep; 2015 Sep; 4():53-61. PubMed ID: 26937411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model.
    Sawamoto K; Tomatsu S
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
    Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.
    Muñoz-Rojas MV; Horovitz DD; Jardim LB; Raymundo M; Llerena JC; de Magalhães Tde S; Vieira TA; Costa R; Kakkis E; Giugliani R
    Mol Genet Metab; 2010 Apr; 99(4):346-50. PubMed ID: 20036175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
    Auclair D; Hein LK; Hopwood JJ; Byers S
    Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
    Whitley CB; Utz JR
    Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation.
    Kunieda T; Simonaro CM; Yoshida M; Ikadai H; Levan G; Desnick RJ; Schuchman EH
    Genomics; 1995 Oct; 29(3):582-7. PubMed ID: 8575749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of arylsulfatase B gene mutations and clinical presentations of Iranian patients with Mucopolysaccharidosis VI.
    Aminzadeh M; Malekpour N; Ghandil P
    Gene; 2019 Jul; 706():1-5. PubMed ID: 31009684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.